Literature DB >> 27056269

T-helper signals restore B-cell receptor signaling in autoreactive anergic B cells by upregulating CD45 phosphatase activity.

Peter Szodoray1, Stephanie M Stanford2, Øyvind Molberg3, Ludvig A Munthe4, Nunzio Bottini2, Britt Nakken5.   

Abstract

BACKGROUND: We recently identified a human B-cell population that is naturally autoreactive and tolerized by functional anergy (BND cells).
OBJECTIVE: We sought to identify the molecular mechanism of how anergic autoreactive BND cells escape functional anergy and whether this process is altered in patients with lupus.
METHODS: Isolated peripheral blood naive and BND cells were cultured with various stimuli, and their activation status was determined by using an intracellular Ca(2+) mobilization assay. Lyn kinase and Syk activities were assessed by using phospho-flow analysis. CD45 phosphatase activity was determined by using a novel flow-based assay, which takes advantage of the fluorogenic properties of phosphorylated coumaryl amino propionic acid, an analog of phosphotyrosine, which can be incorporated into peptides. Real-time quantitative PCR was used to quantitate LYN, SYK, and CD45 mRNA.
RESULTS: T-helper signals reversed the state of anergy, allowing BND cells to fully respond to antigenic stimulation by restoring signaling through the B-cell receptor (BCR). The mechanism was dependent on increased activity of the tyrosine phosphatase CD45 and CD45-dependent activation of Lyn and Syk. CD45 phosphatase activity was increased by T-cell help both in BND and naive B cells. Furthermore, we found that BND cells obtained from patients with systemic lupus erythematosus exhibited increased CD45 activity and BCR-signaling capacity, thus being less tolerized than BND cells from healthy control subjects.
CONCLUSION: Our findings suggest that CD45 is a key regulator of BCR-signaling thresholds mediated by T-cell help. This raises the possibility that BND cells could represent precursors of autoantibody-secreting plasma cells and suggests a role for these autoreactive B cells in contributing to autoimmunity if not properly controlled.
Copyright © 2016 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B-cell anergy; CD45 phosphatase activity; T-cell help; break of tolerance; systemic lupus erythematosus

Mesh:

Substances:

Year:  2016        PMID: 27056269     DOI: 10.1016/j.jaci.2016.01.035

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

Review 1.  Fluorogenic probes for imaging cellular phosphatase activity.

Authors:  Brandon S McCullough; Amy M Barrios
Journal:  Curr Opin Chem Biol       Date:  2020-05-26       Impact factor: 8.822

2.  Hyperprolactinemia is associated with a high prevalence of serum autoantibodies, high levels of inflammatory cytokines and an abnormal distribution of peripheral B-cell subsets.

Authors:  Yaoyang Liu; Zhiguo Zhang; Qianmei Jin; Yang Liu; Zijian Kang; Yongbao Huo; Zhengwen He; Xu Feng; Jian Yin; Xin Wu; Huaizhou Wang; Huji Xu
Journal:  Endocrine       Date:  2019-03-18       Impact factor: 3.633

3.  Impaired B cell anergy is not sufficient to breach tolerance to nuclear antigen in Vκ8/3H9 lupus-prone mice.

Authors:  Kieran P Manion; Yuriy Baglaenko; Nan-Hua Chang; Nafiseh Talaei; Joan E Wither
Journal:  PLoS One       Date:  2020-07-28       Impact factor: 3.240

4.  A replication-incompetent CD154/40L recombinant vaccinia virus induces direct and macrophage-mediated antitumor effects in vitro and in vivo.

Authors:  Valeria Governa; Alvaro Brittoli; Valentina Mele; Maurizio Pinamonti; Luigi Terracciano; Simone Muenst; Giandomenica Iezzi; Giulio Cesare Spagnoli; Paul Zajac; Emanuele Trella
Journal:  Oncoimmunology       Date:  2019-02-14       Impact factor: 8.110

5.  Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.

Authors:  Sarah Y Weißenberg; Franziska Szelinski; Eva Schrezenmeier; Ana-Luisa Stefanski; Annika Wiedemann; Hector Rincon-Arevalo; Anna Welle; Annemarie Jungmann; Karl Nordström; Jörn Walter; Juliana Imgenberg-Kreuz; Gunnel Nordmark; Lars Rönnblom; Prathyusha Bachali; Michelle D Catalina; Amrie C Grammer; Peter E Lipsky; Andreia C Lino; Thomas Dörner
Journal:  Front Immunol       Date:  2019-09-24       Impact factor: 7.561

6.  Metabolic preconditioning in CD4+ T cells restores inducible immune tolerance in lupus-prone mice.

Authors:  Christopher S Wilson; Blair T Stocks; Emilee M Hoopes; Jillian P Rhoads; Kelsey L McNew; Amy S Major; Daniel J Moore
Journal:  JCI Insight       Date:  2021-10-08

7.  SARS-CoV-2 infection relaxes peripheral B cell tolerance.

Authors:  Moriah J Castleman; Megan M Stumpf; Nicholas R Therrien; Mia J Smith; Kelsey E Lesteberg; Brent E Palmer; James P Maloney; William J Janssen; Kara J Mould; J David Beckham; Roberta Pelanda; Raul M Torres
Journal:  J Exp Med       Date:  2022-04-14       Impact factor: 17.579

8.  T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation.

Authors:  John F Imbery; Julia Heinzelbecker; Jenny K Jebsen; Marc McGowan; Camilla Myklebust; Nunzio Bottini; Stephanie M Stanford; Sigrid S Skånland; Anders Tveita; Geir E Tjønnfjord; Ludvig A Munthe; Peter Szodoray; Britt Nakken
Journal:  Br J Haematol       Date:  2022-06-02       Impact factor: 8.615

Review 9.  Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus.

Authors:  Thomas Dörner; Franziska Szelinski; Andreia C Lino; Peter E Lipsky
Journal:  RMD Open       Date:  2020-07

10.  Integration of T helper and BCR signals governs enhanced plasma cell differentiation of memory B cells by regulation of CD45 phosphatase activity.

Authors:  Peter Szodoray; Tor Kristian Andersen; Julia Heinzelbecker; John F Imbery; Peter C Huszthy; Stephanie M Stanford; Bjarne Bogen; Ole B Landsverk; Nunzio Bottini; Anders Tveita; Ludvig A Munthe; Britt Nakken
Journal:  Cell Rep       Date:  2021-08-10       Impact factor: 9.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.